Leadership Overview
Cambrex has 5 executives leading key functions including strategy, operations, finance, human resources, and drug product development.
Driven by a commitment to advancing pharmaceutical innovation, Cambrex operates as a leading global contract development and manufacturing organization, providing comprehensive drug substance, drug product, and analytical services across the entire drug lifecycle.
Driven by a commitment to advancing pharmaceutical innovation, Cambrex operates as a leading global contract development and manufacturing organization, providing comprehensive drug substance, drug product, and analytical services across the entire drug lifecycle.
Leadership Roles at Cambrex
Thomas Loewald - Chief Executive Officer
Thomas Loewald, the Chief Executive Officer at Cambrex, directs the overarching strategy and global operations of the contract development and manufacturing organization. Loewald guides the company's mission to provide comprehensive drug substance, drug product, and analytical services throughout the drug lifecycle. Overseeing a team of experts across North America and Europe, the Chief Executive Officer ensures Cambrex remains a trusted partner for both branded and generic markets. This leadership involves driving innovation in API and finished dosage form development and manufacturing, leveraging over 40 years of industry experience. By focusing on specialized drug substance technologies and advanced manufacturing capabilities, Thomas Loewald positions Cambrex for sustained growth and market leadership in the pharmaceutical sector.
Robert Green - Executive VP & Chief Financial Officer
Robert Green, the Executive VP & Chief Financial Officer at Cambrex, directs all financial strategy, planning, and reporting for the global organization. Green manages capital allocation, investment initiatives, and financial risk mitigation to support Cambrex's growth objectives. The Executive VP & Chief Financial Officer ensures robust financial controls and drives fiscal discipline across all business units, including drug substance and drug product manufacturing. By overseeing financial operations in North America and Europe, Robert Green provides critical insights for strategic decision-making and investor relations. This leadership role is essential for maintaining the company's financial health and enabling its expansion into new technologies and markets, solidifying Cambrex's position as a leading CDMO.
Richard Lifsitz - Chief Operating Officer
Richard Lifsitz, the Chief Operating Officer at Cambrex, oversees the day-to-day operational execution and efficiency across the company's global network. Lifsitz manages the integration of diverse manufacturing capabilities, including continuous flow, controlled substances, and highly potent API production. The Chief Operating Officer ensures seamless delivery of drug substance, drug product, and analytical services, supporting clients from early-stage development through commercial manufacturing. By optimizing production processes and supply chain logistics, Richard Lifsitz enhances the company's capacity to serve both North American and European markets. This role is critical in maintaining Cambrex's reputation for quality and reliability in the branded and generic pharmaceutical sectors, driving operational excellence to meet evolving client needs.
Bruno Biscaro - President, Drug Products
Bruno Biscaro, the President, Drug Products at Cambrex, spearheads the strategic direction and operational oversight of the company's drug product development and manufacturing services. Biscaro drives innovation in conventional and specialty dosage forms, including oral solids, semi-solids, liquids, and complex formulations like modified-release and bi-layer tablets. The President, Drug Products ensures the seamless integration of these capabilities with drug substance services, offering clients a comprehensive lifecycle solution. By focusing on advanced manufacturing technologies and quality assurance, Bruno Biscaro supports the delivery of critical pharmaceutical products to global markets from North America and Europe. This leadership role is pivotal in expanding Cambrex's offerings and reinforcing its position as a premier CDMO.
Dottie Brienza - Chief Human Resources Officer
Dottie Brienza, the Chief Human Resources Officer at Cambrex, leads the strategic development and execution of all human capital initiatives across the global enterprise. Brienza cultivates a high-performance culture, focusing on talent acquisition, employee development, and retention to support Cambrex's expanding team of experts. The Chief Human Resources Officer ensures alignment between workforce capabilities and the company's mission to deliver comprehensive drug substance, drug product, and analytical services. By fostering an environment that values expertise and innovation, Dottie Brienza plays a vital part in attracting and retaining the specialized talent required for advanced pharmaceutical manufacturing in North America and Europe. This role is fundamental to sustaining Cambrex's operational excellence and client partnerships.
Explore Leadership Teams in Manufacturing
Founded in 1974, Apotex is a proud Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
Company Leadership
TM
CV
MG
Sarepta Therapeutics, Inc. is a global commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company is focused on the discovery, development, and commercialization of precision genetic medicines for rare diseases, with particular leadership in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. Sarepta's multi-platform Precision Genetic Medicine Engine spans gene therapy, RNA-targeted therapeutics, and gene editing modalities. The company holds multiple FDA-approved treatments and maintains a broad pipeline of programs across neuromuscular and central nervous system disorders. Sarepta operates globally with locations across North America, Europe, and Asia, and trades on the NASDAQ under the ticker symbol SRPT.
Company Leadership AN
KM
IE
WT
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrows health challenges. We are Amneal and We make healthy possible.
Company Leadership
HK
Alkermes plc is a global biopharmaceutical enterprise that specialises in developing and commercialising innovative medicines for people living with complex psychiatric and neurological disorders. Headquartered in Dublin, Ireland, the company combines deep neuroscience expertise with patient‑inspired science to pursue treatments for conditions such as addiction, schizophrenia, bipolar disorder, opioid dependence and other central nervous system diseases. Its approach integrates scientific research, clinical development and specialised commercial infrastructure to deliver both marketed medicines and investigational candidates, aiming to address serious unmet medical needs and improve how chronic neurological and mental health conditions are managed.
Company Leadership SS
Frequently Asked Questions Regarding Cambrex Top Executives and Leadership Team
